Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer

Lancet Oncol. 2022 Feb;23(2):193-195. doi: 10.1016/S1470-2045(21)00715-4. Epub 2021 Dec 23.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • BNT162 Vaccine / adverse effects
  • BNT162 Vaccine / immunology*
  • Female
  • Humans
  • Immunization, Secondary / adverse effects*
  • Immunogenicity, Vaccine / immunology*
  • Male
  • Middle Aged
  • Neoplasms / immunology*
  • Neoplasms / therapy

Substances

  • BNT162 Vaccine